Fondazione GIMEMA - Franco Mandelli Onlus

What Fondazione GIMEMA - Franco Mandelli Onlus does

Fondazione GIMEMA - Franco Mandelli Onlus is an Italian non-profit foundation (ONLUS) established in 1982, headquartered in Rome, that promotes, manages, and coordinates independent clinical research on adult haematological diseases. The foundation operates through a national cooperative network comprising almost all Italian haematology centres (140+) and more than 60 standardized molecular biology laboratories, running observational, experimental, and biological studies in leukaemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphoproliferative syndromes, multiple myeloma, and related non-neoplastic conditions. In 2025 it conducted 54 clinical trials managing over 16,000 patients and produced 50 publications in major scientific journals.

Its core operational infrastructure is the GIMEMA Data Centre in Rome — a certified, multidisciplinary unit coordinating clinical trial design, conduct, data management, pharmacovigilance, biostatistics, and publication. Built on top of this is LabNet, a national network of disease-specific platforms (LabNet CML, LabNet AML, JakNet, LabNet MDS, LabNet NGS) that standardize molecular diagnostics across Italy and have cumulatively performed 200,000 examinations on 15,000 patients over 20 years. Educational and dissemination assets include the GIMEMA Virtual Microscope (an interactive e-learning platform with high-resolution virtual microscopy for cytomorphology training, built on REDCap), the GIMEMA Informazione news channel, the Hematology Weekly Digest, the Health Outcomes Research Unit for quality-of-life studies, the Fondo per le Idee research grants program, and a Level I Master in Clinical Trial Management co-developed with Università degli Studi di Roma Tor Vergata.

As a non-profit, GIMEMA does not commercialize products or charge for its core services; the foundation is funded through donations, the Italian 5x1000 tax designation, grants, and institutional/pharmaceutical partnerships — most prominently Novartis (for LabNet) and AIL (Associazione Italiana contro le Leucemie-linfomi e mieloma). Nine pathology-specific Working Parties organize research across haematology subspecialties, and the foundation is governed by a Board of Directors with Marco Vignetti as President. All operations are Italy-based, the Data Centre is described as certified at European level for clinical trial management under EU Regulation 536/2014, and the organization operates in compliance with GDPR.

Name

Fondazione GIMEMA - Franco Mandelli Onlus

Legal name

Fondazione GIMEMA - Franco Mandelli ONLUS

Website

https://gimema.it

Company type

Private

Founded year

1982

Operating status

Operating

Headcount range

51–100 employees

Short description

Italian non-profit foundation founded in 1982 that coordinates independent clinical research in adult haematological diseases through a national network of 140+ haematology centres, 60+ labs, and a centralized Data Centre.

Ownership category

akta.pro rank

Product category

Hematology Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro industry

PRIMARYHLAFAAAM

Hospital-Integrated Cancer Centers (Acute Oncology Programs)

Healthcare & Life Sciences/Healthcare Providers & Systems/Acute Care Hospitals & Health Systems

SECONDARYHLAGANAB

Proteomics & Mass Spectrometry Services

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

• Clinical trial coordination
• Hematology clinical research
• Molecular diagnostic network
• Medical professional training
• Nonprofit medical research

Headquarters

HQ city

Rome

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Revenue model

1. Research Funding and Donations: GIMEMA conducts independent clinical research funded through donations, 5x1000 tax designation, and institutional funding. The foundation receives support from organizations like AIL (Associazione Italiana contro le Leucemie-linfomi e mieloma) and pharmaceutical partners like Novartis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Fondazione GIMEMA is an Italian nonprofit research foundation that promotes, manages, and coordinates independent clinical research protocols on adult haematological diseases (leukaemias, lymphomas, myeloproliferative neoplasms, myelodysplastic syndromes, multiple myeloma). It operates a national network of 140+ haematology centres and 60+ standardized laboratories, runs the LabNet molecular diagnostics network, manages clinical trials through its Rome-based Data Centre, and delivers professional training through e-learning platforms and a Master's degree program.

Product overview

Fondazione GIMEMA operates as a clinical research coordination foundation managing a multi-platform portfolio. The core infrastructure consists of the Data Centre in Rome coordinating clinical trials, and LabNet — a national molecular diagnostics network with disease-specific platforms (LabNet CML, LabNet AML, JakNet, LabNet MDS, LabNet NGS) connecting hematologists with standardized laboratories. The educational portfolio centers on GIMEMA Virtual Microscope (GVM), an interactive e-learning platform incorporating the GIMEMA-microscope digital software for cytomorphology training (Percorsi di Citomorfologia) and pathological anatomy pathways. Additional offerings include the Health Outcomes Research Unit for quality of life studies, GIMEMA Informazione news channel, the Hematology Weekly Digest newsletter, and a university Master program in clinical trial management. The foundation conducted 54 clinical trials in 2025 managing over 16,000 patients across 140+ Italian centers.

Differentiator

Problem solved

Functional benefit

Brands

• LabNet: National network connecting hematologists with molecular biology diagnostic laboratories across Italy, covering CML, AML, myeloproliferative neoplasms, and MDS.
• GIMEMA Virtual Microscope (GVM)
• GIMEMA Informazione
• Hematology Weekly Digest
• Fondo per le Idee

Products and services

• LabNet

Quantifiable outcome

• 54 clinical trials conducted in 2025
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Università degli Studi di Roma Tor VergatacoreStrategic or Co-development PartnerGIMEMA collaborates with Roma Tor Vergata University's Scuola IaD to deliver the Master's degree in Clinical Trial Management in Haematology and Oncology. The Master provides professional training in managing haematological and oncological clinical trials.
• ForwardminorStrategic or Co-development PartnerGIMEMA collaborates with Forward on events focused on clinical data, including Real World Data, synthetic data for clinical research, and missing data in clinical trials.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Fondazione Italiana Linfomi (FIL): Italian non-profit cooperative running independent clinical trials in lymphoma, with similar multi-centre network model and Data Centre structure. Closest structural peer to GIMEMA within Italy.
• European LeukemiaNet (ELN): Pan-European network coordinating clinical research and standardization in leukemia, including CML/AML/MDS — same disease focus as GIMEMA but at multi-country scale. Direct functional peer for hematology trial coordination.
• German Lymphoma-Leukemia Study Group (GLSG/DSHNHL): German clinical trials cooperative for lymphoma and leukemia, mirroring GIMEMA's cooperative model and standardized trial coordination approach.
• LYSA (Lymphoma Study Association): French cooperative group coordinating clinical trials in lymphoma with multi-centre network across France. Equivalent role to GIMEMA in a single national market.

Broad incumbents

• European Hematology Association (EHA): Pan-European professional society for hematology, including research coordination, training, and guidelines. Broader remit and geographic scope than GIMEMA but overlapping educational and research missions.
• National Comprehensive Cancer Network (NCCN): US-based not-for-profit alliance of major cancer centers producing clinical guidelines and coordinating research. Equivalent national-coordinator role for oncology as GIMEMA plays for Italian hematology.
• ECOG-ACRIN Cancer Research Group: Large US cooperative group running multi-centre oncology clinical trials including hematologic malignancies. Comparable operational model at national scale.
• EBMT - European Society for Blood and Marrow Transplantation: European organization coordinating hematopoietic stem cell transplantation research and registries, with overlapping hematology trial coordination mandate.

Regional players

• AIRC - Italian Foundation for Cancer Research: Major Italian non-profit funding cancer research broadly, including hematology. Similar non-profit funding model and Italian-only focus but covers all cancers rather than hematology specifically.
• AIL - Associazione Italiana contro le Leucemie-linfomi e mieloma: Italian non-profit patient association supporting hematology research and patient care, including direct funding of GIMEMA. Adjacent mission but patient-facing rather than research-coordinating.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@CentroDati
• Facebookfacebook.com/GIMEMA
• LinkedInlinkedin.com/company/fondazionegimema

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fondazione GIMEMA - Franco Mandelli Onlus